• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非格司亭、来格司亭和培非格司亭在淋巴增殖性恶性肿瘤患者外周血祖细胞动员中的应用

Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies.

作者信息

Ria Roberto, Reale Antonia, Melaccio Assunta, Racanelli Vito, Dammacco Franco, Vacca Angelo

机构信息

Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy,

出版信息

Clin Exp Med. 2015 May;15(2):145-50. doi: 10.1007/s10238-014-0282-9. Epub 2014 Apr 11.

DOI:10.1007/s10238-014-0282-9
PMID:24722996
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4412650/
Abstract

Patients with lymphoproliferative disorders, candidate to autologous stem cell transplantation (ASCT), require mobilization with chemotherapy and granulocyte colony -stimulating factor (G-CSF). This study looked for differences in hematopoietic peripheral stem cells (HPSCs) mobilization in response to the three available G-CSFs, namely lenograstim, filgrastim, and pegfilgrastim. Between 2000 and 2012, 146 patients (66 M and 80 F) who underwent ASCT for multiple myeloma, non-Hodgkin's lymphoma or Hodgkin's lymphoma were studied. All patients received induction therapy and then a mobilization regimen with cyclophosphamide plus lenograstim, or filgrastim, or pegfilgrastim. From days 12 to 14, HPSCs were collected by two to three daily leukaphereses. Our results show that high-dose cyclophosphamide plus lenograstim achieved adequate mobilization and the collection target more quickly and with fewer leukaphereses as compared to filgrastim and pegfilgrastim. No differences between the three regimens were observed regarding toxicity and days to WBC and platelet recovery. Thus, lenograstim may represent the ideal G-CSF for PBSC mobilization in patients with lymphoproliferative diseases. Further studies are needed to confirm these results and better understand the biological bases of these differences.

摘要

适合自体干细胞移植(ASCT)的淋巴增殖性疾病患者需要通过化疗和粒细胞集落刺激因子(G-CSF)进行动员。本研究探寻了三种可用的G-CSF,即来格司亭、非格司亭和培非格司亭在动员造血外周干细胞(HPSC)方面的差异。在2000年至2012年期间,对146例因多发性骨髓瘤、非霍奇金淋巴瘤或霍奇金淋巴瘤接受ASCT的患者(66例男性和80例女性)进行了研究。所有患者均接受诱导治疗,然后采用环磷酰胺加利妥昔单抗,或非格司亭,或培非格司亭进行动员方案。从第12天到第14天,通过每天进行两到三次白细胞分离术采集HPSC。我们的结果表明,与非格司亭和培非格司亭相比,高剂量环磷酰胺加利妥昔单抗能更快地实现充分动员并达到采集目标,且白细胞分离术次数更少。在毒性以及白细胞和血小板恢复天数方面,三种方案之间未观察到差异。因此,来格司亭可能是淋巴增殖性疾病患者PBSC动员的理想G-CSF。需要进一步研究来证实这些结果,并更好地理解这些差异的生物学基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/769b/4412650/f0409ff10e3b/10238_2014_282_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/769b/4412650/f0409ff10e3b/10238_2014_282_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/769b/4412650/f0409ff10e3b/10238_2014_282_Fig1_HTML.jpg

相似文献

1
Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies.非格司亭、来格司亭和培非格司亭在淋巴增殖性恶性肿瘤患者外周血祖细胞动员中的应用
Clin Exp Med. 2015 May;15(2):145-50. doi: 10.1007/s10238-014-0282-9. Epub 2014 Apr 11.
2
Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.对于接受自体外周血干细胞移植的患者,低剂量来格司亭在外周血干细胞动员和移植方面与标准剂量非格司亭同样有效:一项随机研究
Am J Hematol. 2008 Aug;83(8):644-8. doi: 10.1002/ajh.21206.
3
A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization.一项比较非格司亭和聚乙二醇化非格司亭在环磷酰胺外周血造血干细胞动员中作用的随机双盲对照试验。
Transfus Apher Sci. 2015 Oct;53(2):196-204. doi: 10.1016/j.transci.2015.03.017. Epub 2015 Mar 30.
4
Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.健康非亲属志愿造血干细胞供者中生物类似物粒细胞集落刺激因子与非格司亭和来格司亭的比较
Ann Hematol. 2017 Oct;96(10):1735-1739. doi: 10.1007/s00277-017-3060-4. Epub 2017 Aug 11.
5
Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122).来那度胺联合粒细胞集落刺激因子动员多发性骨髓瘤患者造血干细胞:前瞻性多中心观察研究(KMM122)。
Cancer Med. 2023 Apr;12(8):9186-9193. doi: 10.1002/cam4.5657. Epub 2023 Mar 23.
6
The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.非格司亭(优保津®)、生物类似药非格司亭(乐保津®)和来格司亭(格拉诺赛特®)作为自体造血干细胞移植一线外周血干细胞动员策略的比较:来自土耳其的单中心经验
Transfus Apher Sci. 2013 Jun;48(3):315-20. doi: 10.1016/j.transci.2013.04.007. Epub 2013 Apr 20.
7
A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.一项比较非格司亭、来格司亭和莫拉司亭联合化疗用于外周血祖细胞动员的随机研究。
Bone Marrow Transplant. 2006 Sep;38(6):407-12. doi: 10.1038/sj.bmt.1705465.
8
Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.培洛昔福作为非霍奇金淋巴瘤或多发性骨髓瘤患者自体干细胞动员的一线和二线策略。
Pharmacotherapy. 2012 Jul;32(7):596-603. doi: 10.1002/j.1875-9114.2012.01096.x.
9
Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim.在骨髓瘤和淋巴瘤患者自体干细胞移植后,培非格司亭生物类似药与培非格司亭、非格司亭和原研培非格司亭的疗效和安全性比较:一项比较研究。
Ann Hematol. 2024 Mar;103(3):947-956. doi: 10.1007/s00277-023-05604-9. Epub 2024 Jan 8.
10
Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.生物类似物粒细胞集落刺激因子与原研粒细胞集落刺激因子在初诊多发性骨髓瘤患者外周血干细胞动员中的疗效比较
Cytotherapy. 2015 Oct;17(10):1485-93. doi: 10.1016/j.jcyt.2015.05.010. Epub 2015 Jul 15.

引用本文的文献

1
Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122).来那度胺联合粒细胞集落刺激因子动员多发性骨髓瘤患者造血干细胞:前瞻性多中心观察研究(KMM122)。
Cancer Med. 2023 Apr;12(8):9186-9193. doi: 10.1002/cam4.5657. Epub 2023 Mar 23.
2
SIRT1-SIRT7 Expression in Patients with Lymphoproliferative Disorders Undergoing Hematopoietic Stem Cell Mobilization.造血干细胞动员的淋巴增殖性疾病患者中SIRT1 - SIRT7的表达
Cancers (Basel). 2022 Feb 25;14(5):1213. doi: 10.3390/cancers14051213.
3
Monocentric Analysis of the Effectiveness and Financial Consequences of the Use of Lenograstim versus Filgrastim for Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma and Myeloma Receiving Chemotherapy and Autologous Stem Cell Transplantation.

本文引用的文献

1
Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.培洛昔福联合 G-CSF 用于 NHL、霍奇金淋巴瘤和多发性骨髓瘤患者的自体干细胞动员:扩展准入计划的结果。
Bone Marrow Transplant. 2013 Jun;48(6):777-81. doi: 10.1038/bmt.2012.219. Epub 2012 Nov 26.
2
New strategies for stem cell mobilization.干细胞动员的新策略。
Mediterr J Hematol Infect Dis. 2012;4(1):e2012066. doi: 10.4084/MJHID.2012.066. Epub 2012 Oct 3.
3
Induction therapy and stem cell mobilization in patients with newly diagnosed multiple myeloma.
淋巴瘤和骨髓瘤患者接受化疗及自体干细胞移植时,使用来格司亭与非格司亭动员外周血祖细胞的有效性及财务后果的单中心分析
J Blood Med. 2020 Apr 2;11:123-130. doi: 10.2147/JBM.S224173. eCollection 2020.
4
Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey.来那度胺和非格司亭用于住院患者发热性中性粒细胞减少症的预防:一项回顾性调查中预防措施的疗效和成本
J Blood Med. 2018 Dec 27;10:21-27. doi: 10.2147/JBM.S186786. eCollection 2019.
5
Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant.在自体造血干细胞移植和同胞异基因移植中,生物类似物非格司亭与来格司亭的使用比较。
Ther Adv Hematol. 2015 Apr;6(2):53-60. doi: 10.1177/2040620714565962.
6
Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis.聚乙二醇化重组人粒细胞刺激因子与重组人粒细胞刺激因子用于自体外周血干细胞动员的自体造血干细胞移植:一项系统评价和荟萃分析。
Bone Marrow Transplant. 2015 Apr;50(4):523-30. doi: 10.1038/bmt.2014.297. Epub 2015 Jan 12.
新诊断多发性骨髓瘤患者的诱导治疗和干细胞动员。
Stem Cells Int. 2012;2012:607260. doi: 10.1155/2012/607260. Epub 2012 May 31.
4
Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.在预先使用普乐沙福的情况下,培格非格司亭与非格司亭为基础的自体造血干细胞动员:疗效和成本分析。
Transfusion. 2012 Nov;52(11):2375-81. doi: 10.1111/j.1537-2995.2012.03579.x. Epub 2012 Mar 8.
5
The ins and outs of hematopoietic stem cells: studies to improve transplantation outcomes.造血干细胞的来龙去脉:改善移植结果的研究。
Stem Cell Rev Rep. 2011 Sep;7(3):590-607. doi: 10.1007/s12015-010-9212-8.
6
Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization.与非格司亭相比,来格司亭可降低多发性骨髓瘤患者干细胞动员时发热事件的发生率。
Leuk Res. 2011 Jul;35(7):899-903. doi: 10.1016/j.leukres.2010.10.029. Epub 2010 Dec 4.
7
A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy.单剂量培非格司亭与每日使用非格司亭对比,以评估恶性淋巴瘤患者在接受大剂量化疗时自体外周造血祖细胞的动员和植入情况。
Transfus Apher Sci. 2010 Dec;43(3):321-326. doi: 10.1016/j.transci.2010.10.001. Epub 2010 Oct 30.
8
Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs.粒细胞集落刺激因子与粒细胞集落刺激因子联合化疗在动员外周血造血干细胞中的比较。
Bone Marrow Transplant. 2010 Feb;45(2):277-81. doi: 10.1038/bmt.2009.150. Epub 2009 Jul 6.
9
Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT.
Bone Marrow Transplant. 2009 May;43(9):669-77. doi: 10.1038/bmt.2009.59. Epub 2009 Mar 23.
10
Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.对于接受自体外周血干细胞移植的患者,低剂量来格司亭在外周血干细胞动员和移植方面与标准剂量非格司亭同样有效:一项随机研究
Am J Hematol. 2008 Aug;83(8):644-8. doi: 10.1002/ajh.21206.